Key facts
- Creative BioTherapeutics’s last known valuation is $20.0M (Jul 2025).
- It has raised $3.9M across 1 recorded rounds; the latest was Seed Round ($947K) in Aug 2023.
- Notable investors include US National Science Foundation.
- Creative BioTherapeutics has filed 4 Form Ds with the SEC since 2021, most recently Jul 2025 ($947K sold to 22 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Creative BioTherapeutics
Funding rounds
1 roundsAbout Creative BioTherapeutics
Operator of a drug discovery company intended to focus on developing a market-disruptive, first-in-class biologic for recurrent and drug-resistant cancers. The company platform aims to address this critical need by targeting recurrent metastatic breast cancer patients and focuses on the root cause of cancer affecting immune evasion and drug resistance, enabling medical professionals to offer treatments for adult and childhood cancers showing tumor regression and potential cures.
- Sector
- Healthcare
- HQ
- Gurnee, IL, United States
- Founded
- 2016
- Employees
- 7
- Website
- creativebio.tech/
- Ownership
- Privately Held (backing)
Creative BioTherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Creative BioTherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Creative BioTherapeutics in its N-PORT filings yet. We sweep new filings monthly.